Laigo Bio is a biotechnology company pioneering protein degradation for targeted therapies. They have developed a novel technology called SureTACs that facilitates the precise removal of proteins located on any cell surface. Their approach involves bispecific antibodies designed to bind membrane targets, promoting the proximity of the target with a membrane-bound E3 ligase, and directing any cell surface target towards lysosomal degradation.